Oxaliplatin-induced Peripheral Neuropathy, Symptoms, Distress and Quality of Life among Korean Patients with Gastrointestinal Cancer
10.5388/aon.2019.19.4.204
- Author:
Hye Jeong JUNG
1
;
Soo jung AHN
;
Yoo Ri YANG
;
Kyoung A KIM
;
Sang Joon SHIN
;
Min Kyu JUNG
;
Sang Hui CHU
Author Information
1. Department of Nursing, Graduate School of Yonsei University, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Oxaliplatin;
Symptom;
Peripheral neuropathy;
Distress;
Quality of life
- MeSH:
Classification;
Cross-Sectional Studies;
Drug Therapy;
Gastrointestinal Neoplasms;
Humans;
Peripheral Nervous System Diseases;
Quality of Life;
Thermometers
- From:Asian Oncology Nursing
2019;19(4):204-213
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was conducted to identify the level of oxaliplatin-induced peripheral neuropathy (OIPN), symptoms, distress, and quality of life (QoL) in gastrointestinal (GI) cancer patients and to identify the factors influencing QoL.METHODS: A total of 123 patients were recruited for this cross-sectional study. Surveys used were the Therapy-Induced Neuropathy Assessment Scale (TNAS) for OIPN, the MD Anderson Symptom Inventory (MDASI-GI) for general symptoms associated with gastrointestinal cancer and its treatment, a distress thermometer, and the Euro Quality of Life Questionnaire 5-Dimensional Classification (EQ-5D) for QoL.RESULTS: The patients were classified into three groups based on their treatment completion time (current, completed less than one year ago, completed more than one year ago). The scores of MDASI-GI and distress were significantly lower in patients who had completed chemotherapy compared to those who were undergoing treatment (p=.04 and .02 respectively). However, TNAS score was significantly higher in patients who completed chemotherapy less than one year ago than the other two groups (p=.001). In multivariate regression models, the OIPN and distress or general symptoms were identified as factors associated with QoL.CONCLUSION: In this study, we identified the symptoms that are factors related to the QoL in patients with GI cancer. In particular, the symptoms of OIPN are reported at significantly increased levels for patients who have finished chemotherapy less than one year ago, so efforts to prevent and manage the symptoms of OIPN are needed in this timeframe. To improve QoL of patients with GI cancer, continuous attention and care are required not only during the treatment of cancer but also after the completion of treatment.
